VEGF Gene Association With Response to Neovascular Age-related Macular Degeneration With Anti-VEGF Agents
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01655589
Verified July 2012 by Institute of Vision, Brasil. Recruitment status was: Recruiting
The main purpose of this study is to investigate the association between VEGF gene polymorphism and the response to intravitreal drugs in neovascular age-related macular degeneration. This is a retrospective review of patients treated between 2008 and 2012 at the Institute of Vision, in Belo Horizonte, Brazil.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
50 Years and older (Adult, Senior)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Eye clinic in Belo Horizonte, Brazil
Diagnosis of neovascular age-related macular degeneration
Visual acuity better than 20/400
Loading dose with three intravitreal injections of anti-VEGF agents, administred one per month over three months
Follow-up period of at least six months
Choroidal neovascularization secondary to any other cause than age-related macular degeneration